Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
AssigneesDaniel C. Javitt, Stephen R. Zukin
InventorsDaniel C. Javitt, Stephen R. Zukin
Life of this patent
Estimating the term…
Abstract
The amino acid glycine in an administered amount of above 0.4 g/Kg/day is used for treating symptoms of psychosis and of schizophrenia.
Claims12
A process for augmenting NMDA receptor-mediated neurotransmition in a human which comprises orally administering to said human at least more than 0.4 g/Kg body wt/day of glycine.
A process for treating a human patient having a psychosis which comprises orally administering to said human at least 0.4 g/Kg body wt/day of glycine.
A process for treating schizophrenia in a human patient which comprises orally administering to said patient at least more than 0.4 g/Kg body wt/day of glycine.
Dependencies are inferred from the claim text.